www.fdanews.com/articles/176325-mercks-keytruda-scores-fourth-breakthrough-designation
Merck’s Keytruda Scores Fourth Breakthrough Designation
April 22, 2016
Merck has received breakthrough therapy designation for Keytruda to treat patients with relapsed or refractory classical Hodgkin’s lymphoma.
The FDA awarded the designation based on data from ongoing Phase 1b KEYNOTE-013 and Phase 2 KEYNOTE-087 studies. It is Keytruda’s fourth breakthrough designation.